The epigenetic role of EZH2 in acute myeloid leukemia
Acute myeloid leukemia (AML), a malignant disease of the bone marrow, is characterized by the clonal expansion of myeloid progenitor cells and a block in differentiation. The high heterogeneity of AML significantly impedes the development of effective treatment strategies. Enhancer of zeste homolog...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PeerJ Inc.
2024-12-01
|
| Series: | PeerJ |
| Subjects: | |
| Online Access: | https://peerj.com/articles/18656.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850169408910000128 |
|---|---|
| author | Jinyong Fang Jingcheng Zhang Lujian Zhu Xiaoru Xin Huixian Hu |
| author_facet | Jinyong Fang Jingcheng Zhang Lujian Zhu Xiaoru Xin Huixian Hu |
| author_sort | Jinyong Fang |
| collection | DOAJ |
| description | Acute myeloid leukemia (AML), a malignant disease of the bone marrow, is characterized by the clonal expansion of myeloid progenitor cells and a block in differentiation. The high heterogeneity of AML significantly impedes the development of effective treatment strategies. Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the polycomb repressive complex 2 (PRC2), regulates the expression of downstream target genes through the trimethylation of lysine 27 on histone 3 (H3K27me3). Increasing evidence suggests that the dysregulation of EZH2 expression in various cancers is closely associated with tumorigenesis. In the review, we examine the role of EZH2 in AML, highlighting its crucial involvement in regulating stemness, proliferation, differentiation, immune response, drug resistance and recurrence. Furthermore, we summarize the application of EZH2 inhibitors in AML treatment and discuss their potential in combination with other therapeutic modalities. Therefore, targeting EZH2 may represent a novel and promising strategy for the treatment of AML. |
| format | Article |
| id | doaj-art-eb588253a2d44ee0b52fa704f3c9e2e6 |
| institution | OA Journals |
| issn | 2167-8359 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | PeerJ Inc. |
| record_format | Article |
| series | PeerJ |
| spelling | doaj-art-eb588253a2d44ee0b52fa704f3c9e2e62025-08-20T02:20:44ZengPeerJ Inc.PeerJ2167-83592024-12-0112e1865610.7717/peerj.18656The epigenetic role of EZH2 in acute myeloid leukemiaJinyong Fang0Jingcheng Zhang1Lujian Zhu2Xiaoru Xin3Huixian Hu4Department of Hematology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang, ChinaDepartment of Hematology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang, ChinaDepartment of Infectious Diseases, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang, ChinaCollege of Life Sciences, Zhejiang Normal University, Jinhua, Zhejiang, ChinaDepartment of Hematology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang, ChinaAcute myeloid leukemia (AML), a malignant disease of the bone marrow, is characterized by the clonal expansion of myeloid progenitor cells and a block in differentiation. The high heterogeneity of AML significantly impedes the development of effective treatment strategies. Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the polycomb repressive complex 2 (PRC2), regulates the expression of downstream target genes through the trimethylation of lysine 27 on histone 3 (H3K27me3). Increasing evidence suggests that the dysregulation of EZH2 expression in various cancers is closely associated with tumorigenesis. In the review, we examine the role of EZH2 in AML, highlighting its crucial involvement in regulating stemness, proliferation, differentiation, immune response, drug resistance and recurrence. Furthermore, we summarize the application of EZH2 inhibitors in AML treatment and discuss their potential in combination with other therapeutic modalities. Therefore, targeting EZH2 may represent a novel and promising strategy for the treatment of AML.https://peerj.com/articles/18656.pdfEZH2AMLEZH2 inhibitorEpigenesisTumorigenesis |
| spellingShingle | Jinyong Fang Jingcheng Zhang Lujian Zhu Xiaoru Xin Huixian Hu The epigenetic role of EZH2 in acute myeloid leukemia PeerJ EZH2 AML EZH2 inhibitor Epigenesis Tumorigenesis |
| title | The epigenetic role of EZH2 in acute myeloid leukemia |
| title_full | The epigenetic role of EZH2 in acute myeloid leukemia |
| title_fullStr | The epigenetic role of EZH2 in acute myeloid leukemia |
| title_full_unstemmed | The epigenetic role of EZH2 in acute myeloid leukemia |
| title_short | The epigenetic role of EZH2 in acute myeloid leukemia |
| title_sort | epigenetic role of ezh2 in acute myeloid leukemia |
| topic | EZH2 AML EZH2 inhibitor Epigenesis Tumorigenesis |
| url | https://peerj.com/articles/18656.pdf |
| work_keys_str_mv | AT jinyongfang theepigeneticroleofezh2inacutemyeloidleukemia AT jingchengzhang theepigeneticroleofezh2inacutemyeloidleukemia AT lujianzhu theepigeneticroleofezh2inacutemyeloidleukemia AT xiaoruxin theepigeneticroleofezh2inacutemyeloidleukemia AT huixianhu theepigeneticroleofezh2inacutemyeloidleukemia AT jinyongfang epigeneticroleofezh2inacutemyeloidleukemia AT jingchengzhang epigeneticroleofezh2inacutemyeloidleukemia AT lujianzhu epigeneticroleofezh2inacutemyeloidleukemia AT xiaoruxin epigeneticroleofezh2inacutemyeloidleukemia AT huixianhu epigeneticroleofezh2inacutemyeloidleukemia |